Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study - PubMed (original) (raw)
Comparative Study
Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study
Loukianos S Rallidis et al. Atherosclerosis. 2004 May.
No abstract available
Similar articles
- A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R. Zelber-Sagi S, et al. Clin Gastroenterol Hepatol. 2006 May;4(5):639-44. doi: 10.1016/j.cgh.2006.02.004. Epub 2006 Apr 17. Clin Gastroenterol Hepatol. 2006. PMID: 16630771 Clinical Trial. - Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Harrison SA, et al. Am J Gastroenterol. 2003 Nov;98(11):2485-90. doi: 10.1111/j.1572-0241.2003.08699.x. Am J Gastroenterol. 2003. PMID: 14638353 Clinical Trial. - Non-alcohol induced steatohepatitis in non-obese patients: treatment with ursodeoxycholic acid.
Bauditz J, Schmidt HH, Dippe P, Lochs H, Pirlich M. Bauditz J, et al. Am J Gastroenterol. 2004 May;99(5):959-60. doi: 10.1111/j.1572-0241.2004.40013.x. Am J Gastroenterol. 2004. PMID: 15128373 No abstract available. - Managing nonalcoholic fatty liver disease: recommendations for family physicians.
Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Grattagliano I, et al. Can Fam Physician. 2007 May;53(5):857-63. Can Fam Physician. 2007. PMID: 17872748 Free PMC article. Review. - Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P, Barkin JS. Hookman P, et al. Am J Gastroenterol. 2003 Sep;98(9):2093-7. doi: 10.1111/j.1572-0241.2003.07670.x. Am J Gastroenterol. 2003. PMID: 14499793 Review.
Cited by
- A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M. Alla VM, et al. Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Drugs. 2013. PMID: 23754124 Review. - Nonalcoholic fatty liver disease: from lipid profile to treatment.
Miura K, Ohnishi H. Miura K, et al. Clin J Gastroenterol. 2012 Oct;5(5):313-21. doi: 10.1007/s12328-012-0315-4. Epub 2012 Jun 17. Clin J Gastroenterol. 2012. PMID: 26181068 - Jaundice due to suspected statin hepatotoxicity: a case series.
Bergmann OM, Kristjansson G, Jonasson JG, Björnsson ES. Bergmann OM, et al. Dig Dis Sci. 2012 Jul;57(7):1959-64. doi: 10.1007/s10620-011-1950-1. Epub 2011 Nov 11. Dig Dis Sci. 2012. PMID: 22075853 - Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury.
Li X, Gao P, Niu J. Li X, et al. Biomed Res Int. 2019 Aug 18;2019:8764093. doi: 10.1155/2019/8764093. eCollection 2019. Biomed Res Int. 2019. PMID: 31531370 Free PMC article. Review. - Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases.
Lee HA, Chang Y, Sung PS, Yoon EL, Lee HW, Yoo JJ, Lee YS, An J, Song DS, Cho YY, Kim SU, Kim YJ. Lee HA, et al. Clin Mol Hepatol. 2022 Jul;28(3):425-472. doi: 10.3350/cmh.2022.0186. Epub 2022 Jul 1. Clin Mol Hepatol. 2022. PMID: 35850495 Free PMC article. Review.